Revenue growth starts recovering
Abbott India Limited’s (AIL) Q4FY21 performance was better than our estimates with revenue growing 14.0% YoY to Rs10.9bn (I-Sec:..
Sales recovery in the offing...
While Q4FY21 results are not strictly comparable on a YoY basis due to pandemic related challenges in the base year, FY21 revenues grew..
Abbott India Ltd. recently announced its performance for the quarter ended December 31, 2020. Following are the key highlights.
Highlights from the Quarter (Q3 FY21)
Weak performance; margins stable
Abbott India Limited’s (AIL) Q3FY21 performance was muted and lower than our estimates. Revenue grew 1.6% YoY to Rs10.9bn (I-Se..
Rupee falls 10 paise to 73.94 against US dollar in early trade
Rupee strengthens against US dollar on Tuesday
Rate decision, US stimulus likely constraints to rupee's further appreciation
Rupee slips on RBI's dovish stance, 'loose' policy
Currency Squeeze: Rupee expected to weaken further
India`s 5G space booming with global, domestic players pitching in
India`s July gasoline sales above pre-pandemic levels - prelim data
Weekly Tech Picks - Max Healthcare Institute Ltd, Aarti Industries Ltd, Godrej Properties Ltd, Indraprastha Gas Ltd By Axis Securities
Market volatility and surfeit of primary issuances to dominate markets
© Copyright 2017 - investmentguruindia | All Rights Reserved. | Crafted By - Digi Interface